Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Clinical trial NCT02729025 · COMPLETED
Trial details
- NCT number
- NCT02729025
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-14
- Primary completion
- 2018-04-05
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.